Severe Psoriasis - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 50

Severe Psoriasis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Severe Psoriasis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Severe Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Severe Psoriasis. Severe Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Severe Psoriasis.
- A review of the Severe Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Severe Psoriasis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Severe Psoriasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Severe Psoriasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Severe Psoriasis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Severe Psoriasis 7
Severe Psoriasis Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Severe Psoriasis Therapeutics – Products under Development by Companies 13
Companies Involved in Severe Psoriasis Therapeutics Development 14
Amgen Inc. 14
Eli Lilly and Company 15
ApoPharma 16
Idera Pharmaceuticals, Inc. 17
Lupin Limited 18
CalciMedica, Inc. 19
Severe Psoriasis – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
brodalumab - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
AMG-811 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AMG-517 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ixekizumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ixekizumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
IMO-3100 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LLL-3348 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Clobetasol Propionate + Etanercept - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CM-2489 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Apo-805-K1 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Severe Psoriasis Therapeutics – Drug Profile Updates 40
Severe Psoriasis – Product Development Milestones 48
Featured News & Press Releases 48
Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables
Number of Products Under Development for Severe Psoriasis, H2 2012 7
Products under Development for Severe Psoriasis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Amgen Inc., H2 2012 14
Eli Lilly and Company, H2 2012 15
ApoPharma, H2 2012 16
Idera Pharmaceuticals, Inc., H2 2012 17
Lupin Limited, H2 2012 18
CalciMedica, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Severe Psoriasis Therapeutics – Drug Profile Updates 40

List of Figures
Number of Products under Development for Severe Psoriasis, H2 2012 7
Products under Development for Severe Psoriasis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25

Customers who bought this item also bought

• Psoriasis - Pipeline Review, H2 2012
• Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2011
• Acute Pain - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Osteonecrosis - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012